Regulus Therapeutics (NASDAQ:RGLS) Announces Quarterly Earnings Results

Regulus Therapeutics (NASDAQ:RGLSGet Rating) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05), MarketWatch Earnings reports. During the same quarter last year, the firm earned ($0.08) EPS.

Regulus Therapeutics stock opened at $0.22 on Friday. Regulus Therapeutics has a 52 week low of $0.16 and a 52 week high of $1.48. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.09. The firm’s 50-day simple moving average is $0.25 and its 200 day simple moving average is $0.30.

Several institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its position in shares of Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares in the last quarter. Morgan Stanley boosted its position in shares of Regulus Therapeutics by 13.0% in the 3rd quarter. Morgan Stanley now owns 564,462 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 64,837 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Regulus Therapeutics by 13.8% in the 3rd quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 81,551 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Regulus Therapeutics by 498.2% in the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 111,100 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Regulus Therapeutics by 21.4% in the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 648,121 shares in the last quarter. Institutional investors and hedge funds own 47.06% of the company’s stock.

A number of research firms have recently weighed in on RGLS. StockNews.com began coverage on shares of Regulus Therapeutics in a research note on Friday. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Regulus Therapeutics in a research note on Tuesday, January 25th. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research note on Friday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Regulus Therapeutics in a research note on Monday, May 9th.

About Regulus Therapeutics (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Featured Articles

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.